1 of 1
Story summary
- The U.S. Food and Drug Administration (FDA) approved Essilor Stellest spectacle lenses for myopia correction in children aged 6 to 12.
- Low-dose atropine can reduce myopic progression by 30% to 60%.
- Dual-focus spectacle lenses and outdoor time of 40–80 minutes daily are effective.
- Orthokeratology can help, but it carries a higher risk of infections.
- The regulatory landscape is evolving, with new products under review in the United States.
